

CCRN CARDIOLOGY HIGHLIGHT SERIES

ESC HIGHLIGHTS 2026



MONDAY, SEPTEMBER 21

7:00 – 8:30 pm ET

Program Overview:

This program covers key clinical trial findings and their implications from the ESC scientific sessions. This program is intended for cardiovascular specialists and primary care physicians.

Learning Objectives:

Following participation in this program, participants will be able to:

- Identify the clinical implications of the new data presented at the scientific sessions
- Examine where the data presented may impact clinical practice guidelines
- Apply the latest evidence-based strategies in clinical practice

Discussion Topics:

- Latest updates in AF management
- What is the impact of a gene silencer in patients with ATTR?
- Practical management of obstructive hypertrophic cardiomyopathy (HCM)
- Are statins safe and effective in the elderly?
- What is the impact of combination statin and Evolocumab at the time of ACS?



Register Now!

Visit: www.ccrnmd.com

For inquiries regarding this program please email us at:
info@ccrnmd.com



Developed by:
 **CCRN**
Collaborative CME and Research Network

SPEAKERS



Milan Gupta

MD, FRCPC, FCCS, CPC(HC)

Assistant Professor,
Department of Medicine,
University of Toronto,
Medical Director,
Collaborative CME and Research Network,
Brampton, ON



Narendra Singh

MD, FRCPC, FCCS, FACC, FAHA

Director, NSC Cardiology,
Clinical Associate Professor,
Medical College of Georgia at Augusta
University and Mercer University,
Medical Director, CCRN USA,
Atlanta, GA

CFPC Accreditation:

This activity has been certified by the College of Family Physicians of Canada for up to 1.5 Mainpro+® Certified Activity credits.

AAFP Accreditation:

Members of the American Academy of Family Physicians are eligible to receive up to 1.5 Prescribed credit hours for attendance at this meeting/event due to a reciprocal agreement with the College of Family Physicians of Canada.

This program has been developed by CCRN and has received unrestricted educational grants and in-kind support from: Amgen, AstraZeneca, and BMS.